Cargando…

MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant?

BACKGROUND: Prevalence of stage 3 chronic kidney disease (CKD) is increasing according to the NHANES study. Prevalence has been calculated using the MDRD study equation for estimating glomerular filtration rate (GFR). Recently, a new estimator based on creatinine, the CKD-EPI equation, has been prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Delanaye, Pierre, Cavalier, Etienne, Mariat, Christophe, Maillard, Nicolas, Krzesinski, Jean-Marie
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891733/
https://www.ncbi.nlm.nih.gov/pubmed/20515483
http://dx.doi.org/10.1186/1471-2369-11-8
_version_ 1782182893958725632
author Delanaye, Pierre
Cavalier, Etienne
Mariat, Christophe
Maillard, Nicolas
Krzesinski, Jean-Marie
author_facet Delanaye, Pierre
Cavalier, Etienne
Mariat, Christophe
Maillard, Nicolas
Krzesinski, Jean-Marie
author_sort Delanaye, Pierre
collection PubMed
description BACKGROUND: Prevalence of stage 3 chronic kidney disease (CKD) is increasing according to the NHANES study. Prevalence has been calculated using the MDRD study equation for estimating glomerular filtration rate (GFR). Recently, a new estimator based on creatinine, the CKD-EPI equation, has been proposed which is presumed to better perform in normal GFR ranges. The aim of the study was to measure the difference in prevalence of stage 3 CKD in a population using either the MDRD or the CKD-EPI study equations. METHODS: CKD screening is organized in the Province of Liège, Belgium. On a voluntary basis, people aged between 45 and 75 years are invited to be screened. GFR is estimated by the MDRD study equation and by the "new" CKD-EPI equations. RESULTS: The population screened consisted in 1992 people (47% of men). Mean serum creatinine was 0.86 ± 0.20 mg/dL. The prevalence of stage 3 CKD in this population using the MDRD or the CKD-EPI equations was 11.04 and 7.98%, respectively. The prevalence of stage 3 CKD is significantly higher with the MDRD study equation (p < 0,0012). CONCLUSIONS: Prevalence of stage 3 CKD varies strongly following the method used for estimating GFR, MDRD or CKD-EPI study equations. Such discrepancies are of importance and must be confirmed and explained by additional studies using GFR measured with a reference method.
format Text
id pubmed-2891733
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28917332010-06-25 MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? Delanaye, Pierre Cavalier, Etienne Mariat, Christophe Maillard, Nicolas Krzesinski, Jean-Marie BMC Nephrol Research article BACKGROUND: Prevalence of stage 3 chronic kidney disease (CKD) is increasing according to the NHANES study. Prevalence has been calculated using the MDRD study equation for estimating glomerular filtration rate (GFR). Recently, a new estimator based on creatinine, the CKD-EPI equation, has been proposed which is presumed to better perform in normal GFR ranges. The aim of the study was to measure the difference in prevalence of stage 3 CKD in a population using either the MDRD or the CKD-EPI study equations. METHODS: CKD screening is organized in the Province of Liège, Belgium. On a voluntary basis, people aged between 45 and 75 years are invited to be screened. GFR is estimated by the MDRD study equation and by the "new" CKD-EPI equations. RESULTS: The population screened consisted in 1992 people (47% of men). Mean serum creatinine was 0.86 ± 0.20 mg/dL. The prevalence of stage 3 CKD in this population using the MDRD or the CKD-EPI equations was 11.04 and 7.98%, respectively. The prevalence of stage 3 CKD is significantly higher with the MDRD study equation (p < 0,0012). CONCLUSIONS: Prevalence of stage 3 CKD varies strongly following the method used for estimating GFR, MDRD or CKD-EPI study equations. Such discrepancies are of importance and must be confirmed and explained by additional studies using GFR measured with a reference method. BioMed Central 2010-06-01 /pmc/articles/PMC2891733/ /pubmed/20515483 http://dx.doi.org/10.1186/1471-2369-11-8 Text en Copyright ©2010 Delanaye et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Delanaye, Pierre
Cavalier, Etienne
Mariat, Christophe
Maillard, Nicolas
Krzesinski, Jean-Marie
MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant?
title MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant?
title_full MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant?
title_fullStr MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant?
title_full_unstemmed MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant?
title_short MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant?
title_sort mdrd or ckd-epi study equations for estimating prevalence of stage 3 ckd in epidemiological studies: which difference? is this difference relevant?
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891733/
https://www.ncbi.nlm.nih.gov/pubmed/20515483
http://dx.doi.org/10.1186/1471-2369-11-8
work_keys_str_mv AT delanayepierre mdrdorckdepistudyequationsforestimatingprevalenceofstage3ckdinepidemiologicalstudieswhichdifferenceisthisdifferencerelevant
AT cavalieretienne mdrdorckdepistudyequationsforestimatingprevalenceofstage3ckdinepidemiologicalstudieswhichdifferenceisthisdifferencerelevant
AT mariatchristophe mdrdorckdepistudyequationsforestimatingprevalenceofstage3ckdinepidemiologicalstudieswhichdifferenceisthisdifferencerelevant
AT maillardnicolas mdrdorckdepistudyequationsforestimatingprevalenceofstage3ckdinepidemiologicalstudieswhichdifferenceisthisdifferencerelevant
AT krzesinskijeanmarie mdrdorckdepistudyequationsforestimatingprevalenceofstage3ckdinepidemiologicalstudieswhichdifferenceisthisdifferencerelevant